Funding for this research was provided by:
National Institutes of Health (K01 HL128791, CA047988, HL043851, HL080467, HL099355, and UM1 CA182913)
Else Kröner-Fresenius-Stiftung (GSO/EKFS 17)
Received: 28 November 2019
Accepted: 2 March 2020
First Online: 17 March 2020
Ethics approval and consent to participate
: Written informed consent was obtained from all participants, and the Women’s Health Study was approved by the Institutional Review Board at Brigham and Women’s Hospital (ExternalRef removed identifier: NCT00000479).
: Not applicable.
: JLR, PMR, and JEB report no disclosures. TK reports having received honoraria from Novartis and Daiichi-Sankyo for lectures on neuroepidemiology and research methods, from Lilly, Newsenselab, and Total for providing methodological advice, and from The BMJ for editorial services. He provided methodological advice for Amgen and CoLucid, for which the Charité - Universitätsmedizin Berlin received unrestricted funds.